Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSECCO: Cemiplimab, Fianlimab, and Ipilimumab in Resectable Melanoma
NCT07511036Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2026
- Primary completion
- May 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab, fianlimab, ipilimumab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cemiplimabfianlimabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07511036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511036.